Madhav Dhodapkar, MBBS

One star
One star
One star
One star
One star

Rating: 5 out of 5 (71 ratings)

Role

Hematology Oncology
Specialty

Myeloma and Plasma Cell Disorders
Research Program

Cancer Immunology
Practicing Since

1994

Request Appointment

Background

Madhav V. Dhodapkar, is the Anise McDaniel Brock Chair and Georgia Research Alliance Eminent Scholar in Cancer Innovation and Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Dhodapkar serves as director of the Winship Center for Cancer Immunology.

Prior to joining Emory, he served as Chief of Hematology, the Arthur H. and Isabel Bunker Professor of Medicine (Hematology), and Professor of Immunobiology at Yale University School of Medicine. An expert in the treatment of multiple myeloma, he also was co-director of the Cancer Immunology Program within the Yale Cancer Center. Other faculty appointments include Myeloma Institute in Little Rock, Arkansas, Memorial Sloan Kettering Cancer Center in New York, New York, and The Rockefeller University in New York, New York.

A board certified hematologist and medical oncologist, Dr. Dhodapkar specializes in the treatment of multiple myeloma and other hematological malignancies. His primary clinical and scholarly focus is the immuno-biology of myeloma and the development of novel biological approaches to treat cancer.
Dr. Dhodapkar received his Medical Degree from the All India Institute of Medical Sciences in New Delhi, and completed his fellowship in hematology and medical oncology at the Mayo Clinic in Rochester, Minnesota.

Titles & Roles

Professor and Anise McDaniel Brock Chair, Department of Hematology and Medical Oncology

Emory University School of Medicine
Georgia Research Alliance Eminent Scholar in Cancer Innovation

Emory University School of Medicine
Director, Center for Cancer Immunology

Winship Cancer Institute of Emory University
Leader, Cancer Immunology Research Program

Winship Cancer Institute of Emory University

Education & Training

Education

Fellowship, Hematology, 1994
Mayo Clinic School of Medicine
Residency, Internal Medicine, 1990
St. Louis University Hospital
Internship, Internal Medicine, 1988
Sinai Samaritan Medical Ctr
Medical Education, , 1988
All india Institute of Medical Sciences

Board Certifications

Medical Oncology
American Board of Internal Medicine, 1995
Hematology
American Board of Internal Medicine, 1994

Professional Memberships

American Society of Hematology
American Society of Clinical Oncology

View Current Clinical Trials


Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase I/II Conditions Multiple Myeloma Location Emory University Hospital Midtown, Winship Cancer Institute
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Phase II Conditions Multiple Myeloma Location Emory University Hospital Midtown, Winship Cancer Institute
Rifaximin in Patients With Monoclonal Gammopathy Phase I Conditions IgA Monoclonal Gammopathy, IgG Monoclonal Gammopathy, IgM Monoclonal Gammopathy, Light Chain Deposition Disease, Monoclonal Gammopathy, Smoldering Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia, Gammopathy, Monoclonal, Gammopathy Igg Location Emory University Hospital Midtown, Winship Cancer Institute

Grants

View Grants

Grant Number	Title
1K12CA237806-01	Emory Clinical Oncology Career Development Award K12 Program
3U54CA260563-02S1	Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
3U54CA260563-02S2	Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
4U54CA260563-02	Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
5K12CA237806-02	Emory Clinical Oncology Career Development Award K12 Program
5K12CA237806-03	Emory Clinical Oncology Career Development Award K12 Program
5R35CA197603-07	HARNESSING HOST RESPONSE TO PREVENT MYELOMA

Publications

Dr. Dhodapkar has authored over 100 scientific publications and is section editor for the Journal of Immunology and associate editor for Blood.

Title/Journal	Authors	Publication Date
Tregs protect against combination checkpoint blockade toxicity induced by TPH and B cell interactions. The Journal of clinical investigation	A Duffy, MI Azeem, S Kanangat, M Yushak, D Lawson, MV Dhodapkar, KM Dhodapkar	02/05/2024
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma. Blood cancer discovery	IM Ghobrial, N Gormley, SK Kumar, MV Mateos, PL Bergsagel, M Chesi, MV Dhodapkar, A Dispenzieri, R Fonseca, G Getz, E Kastritis, SY Kristinsson, JA Martinez-Climent, S Manier, CR Marinac, F Maura, GJ Morgan, FE Davies, O Nadeem, M Nuvolone, B Paiva, E O'Donnell, F Prosper, UA Shah, R Sklavenitis-Pistofidis, AS Sperling, GS Vassiliou, NC Munshi, PE Castle, KC Anderson, JF San Miguel	01/05/2024
TIM-3⁺ CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies. Science immunology	SA Minnie, OG Waltner, P Zhang, S Takahashi, NS Nemychenkov, KS Ensbey, CR Schmidt, SRW Legg, M Comstock, JR Boiko, E Nelson, SS Bhise, AB Wilkens, M Koyama, MV Dhodapkar, M Chesi, SR Riddell, DJ Green, A Spencer, SN Furlan, GR Hill	19/04/2024
Immune status and selection of patients for immunotherapy in myeloma: a Proposal. Blood advances	MV Dhodapkar	02/04/2024
Immune-Pathogenesis of Myeloma. Hematology/oncology clinics of North America	MV Dhodapkar	01/04/2024
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101). medRxiv : the preprint server for health sciences	JA Hill, MJ Martens, JH Young, K Bhavsar, J Kou, M Chen, LW Lee, A Baluch, MV Dhodapkar, R Nakamura, K Peyton, DS Howard, U Ibrahim, Z Shahid, P Armistead, P Westervelt, J McCarty, J McGuirk, M Hamadani, S DeWolf, K Hosszu, E Sharon, A Spahn, AA Toor, S Waldvogel, LM Greenberger, JJ Auletta, MM Horowitz, ML Riches, MA Perales	25/01/2024
Role of Natural Killer T (NKT) Cells in Myeloma Biology and Therapy. Critical reviews in oncogenesis	MV Dhodapkar	01/01/2024
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood cancer journal	SA Scott, EM Marin, KT Maples, NS Joseph, CC Hofmeister, VA Gupta, MV Dhodapkar, JL Kaufman, S Lonial, AK Nooka	20/12/2023
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer. NPJ vaccines	RM Valanparambil, L Lai, MA Johns, M Davis-Gardner, SL Linderman, TO McPherson, A Chang, A Akhtar, ELB Gamarra, H Matia, AA McCook-Veal, J Switchenko, TH Nasti, F Green, M Saini, A Wieland, BA Pinsky, D Solis, MV Dhodapkar, J Carlisle, S Ramalingam, R Ahmed, MS Suthar	21/11/2023
Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against Wuhan-WT, delta and omicron BA1, BA2 spike trimers. iScience	N Cheedarla, HP Verkerke, S Potlapalli, KB McLendon, A Patel, F Frank, WH O'Sick, S Cheedarla, TJ Baugh, GL Damhorst, H Wu, D Graciaa, F Hudaib, DN Alter, J Bryksin, EA Ortlund, J Guarner, S Auld, S Shah, W Lam, D Mattoon, JM Johnson, DH Wilson, MV Dhodapkar, SR Stowell, AS Neish, JD Roback	17/11/2023
Harnessing Dendritic Cells: Next Frontier for Durable Immune Control in Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research	MV Dhodapkar	14/11/2023
Trans-vaccenic acid reprograms CD8⁺ T cells and anti-tumour immunity. Nature	H Fan, S Xia, J Xiang, Y Li, MO Ross, SA Lim, F Yang, J Tu, L Xie, U Dougherty, FQ Zhang, Z Zheng, R Zhang, R Wu, L Dong, R Su, X Chen, T Althaus, PA Riedell, PB Jonker, A Muir, GB Lesinski, S Rafiq, MV Dhodapkar, W Stock, O Odenike, AA Patel, J Opferman, T Tsuji, J Matsuzaki, H Shah, B Faubert, SE Elf, B Layden, BM Bissonnette, YY He, J Kline, H Mao, K Odunsi, X Gao, H Chi, C He, J Chen	01/11/2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity. Research square	A Moreno, K Manning, MI Azeem, AK Nooka, M Ellis, RJ Manalo, JM Switchenko, B Wali, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar, MS Suthar	21/09/2023
Role of B cells in immune-related adverse events following checkpoint blockade. Immunological reviews	KM Dhodapkar, A Duffy, MV Dhodapkar	01/09/2023
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction. JCO oncology practice	LF Sun, KT Maples, KH Hall, Y Liu, Y Cao, NS Joseph, CC Hofmeister, JL Kaufman, M Dhodapkar, AK Nooka, S Lonial, RD Harvey	01/09/2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity. bioRxiv : the preprint server for biology	A Moreno, K Manning, MI Azeem, AK Nooka, M Ellis, RJ Manalo, JM Switchenko, B Wali, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar, MS Suthar	22/08/2023
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. The Journal of clinical investigation	MH Robinson, NY Villa, DL Jaye, AK Nooka, A Duffy, SS McCachren, J Manalo, JM Switchenko, S Barnes, S Potdar, MI Azeem, AA Horvat, VC Parihar, J Gong, Y Liang, GH Smith, VA Gupta, LH Boise, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar	01/08/2023
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies. Blood advances	A Chang, JL Koff, L Lai, VM Orellana-Noia, M Surati, AMK Leal, ML Ellis, B Wali, A Moreno, SL Linderman, CB O'Leary, PB Allen, MC Churnetski, MV Dhodapkar, MS Suthar, JB Cohen, R Ahmed	13/06/2023
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop. Clinical lymphoma, myeloma & leukemia	E Terpos, P Neri, NWCJ van de Donk, M D'Agostino, S Parekh, S Jagannath, H Ludwig, DE Avigan, MV Dhodapkar, NS Raje	01/06/2023
SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study. EClinicalMedicine	JA Hill, MJ Martens, JH Young, K Bhavsar, J Kou, M Chen, LW Lee, A Baluch, MV Dhodapkar, R Nakamura, K Peyton, Z Shahid, P Armistead, P Westervelt, J McCarty, J McGuirk, M Hamadani, S DeWolf, K Hosszu, E Sharon, A Spahn, AA Toor, S Waldvogel, LM Greenberger, JJ Auletta, MM Horowitz, ML Riches, MA Perales	01/05/2023
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma. Journal for immunotherapy of cancer	S Raghunandan, M Pauly, WG Blum, M Qayed, MV Dhodapkar, M Elkhalifa, B Watkins, M Schoettler, E Horwitz, S Parikh, S Chandrakasan, K Leung, E Bryson, L Deeb, JL Kaufman, D Worthington-White, A Alazraki, JM Schecter, D Madduri, CC Jackson, E Zudaire, A Taraseviciute-Morris, A Babich, T Nesheiwat, M Vogel, N Lendvai, L Pacaud, KM Williams	01/05/2023
The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception. American journal of hematology	MV Dhodapkar	01/03/2023
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections. Blood cancer discovery	MI Azeem, AK Nooka, U Shanmugasundaram, N Cheedarla, S Potdar, RJ Manalo, A Moreno, JM Switchenko, S Cheedarla, DB Doxie, R Radzievski, ML Ellis, KE Manning, B Wali, RM Valanparambil, KT Maples, E Baymon, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, JD Roback, A Sette, R Ahmed, MS Suthar, AS Neish, MV Dhodapkar, KM Dhodapkar	01/03/2023
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience. Blood cancer journal	KT Maples, KH Hall, NS Joseph, CC Hofmeister, V Gupta, MV Dhodapkar, JL Kaufman, AK Nooka, S Lonial	20/02/2023
Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma. NPJ genomic medicine	W Pilcher, BE Thomas, SS Bhasin, RG Jayasinghe, L Yao, E Gonzalez-Kozlova, S Dasari, S Kim-Schulze, A Rahman, J Patton, M Fiala, G Cheloni, T Kourelis, MV Dhodapkar, R Vij, S Mehr, M Hamilton, HJ Cho, D Auclair, DE Avigan, SK Kumar, S Gnjatic, L Ding, M Bhasin	26/01/2023
Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies. Cancer research communications	A Chang, A Akhtar, L Lai, VM Orellana-Noia, SL Linderman, AA McCook-Veal, JM Switchenko, M Saini, RM Valanparambil, KA Blum, PB Allen, MJ Lechowicz, JT Romancik, A Ayers, A Leal, CB O'Leary, MC Churnetski, K Baird, M Kives, J Wrammert, AK Nooka, JL Koff, MV Dhodapkar, MS Suthar, JB Cohen, R Ahmed	01/12/2022
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	RM Valanparambil, J Carlisle, SL Linderman, A Akthar, RL Millett, L Lai, A Chang, AA McCook-Veal, J Switchenko, TH Nasti, M Saini, A Wieland, KE Manning, M Ellis, KM Moore, SL Foster, K Floyd, ME Davis-Gardner, VV Edara, M Patel, C Steur, AK Nooka, F Green, MA Johns, F O'Brein, U Shanmugasundaram, VI Zarnitsyna, H Ahmed, LE Nyhoff, G Mantus, M Garett, S Edupuganti, M Behra, R Antia, J Wrammert, MS Suthar, MV Dhodapkar, S Ramalingam, R Ahmed	20/11/2022
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. Blood cancer discovery	KM Dhodapkar, AD Cohen, A Kaushal, AL Garfall, RJ Manalo, AR Carr, SS McCachren, EA Stadtmauer, SF Lacey, JJ Melenhorst, CH June, MC Milone, MV Dhodapkar	02/11/2022
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade. Clinical lung cancer	BE Osta, J Carlisle, C Steuer, S Pakkala, T Leal, M Dhodapkar, Y Liu, Z Chen, T Owonikoko, S Ramalingam	01/11/2022
Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis. Cancer research communications	L Yao, RG Jayasinghe, BH Lee, SS Bhasin, W Pilcher, DB Doxie, E Gonzalez-Kozlova, S Dasari, MA Fiala, Y Pita-Juarez, M Strausbauch, G Kelly, BE Thomas, SK Kumar, HJ Cho, E Anderson, MC Wendl, T Dawson, D D'souza, ST Oh, G Cheloni, Y Li, JF DiPersio, AH Rahman, KM Dhodapkar, S Kim-Schulze, R Vij, IS Vlachos, S Mehr, M Hamilton, D Auclair, T Kourelis, D Avigan, MV Dhodapkar, S Gnjatic, MK Bhasin, L Ding	01/10/2022
CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Clinical lymphoma, myeloma & leukemia	A Chang, L Lai, A Akhtar, S Linderman, V Orellana-Noia, M Saini, R Valanparambil, K Blum, P Allen, M Lechowicz, J Romancik, A Ayers, C O'Leary, M Churnetski, M Kives, A Nooka, J Koff, M Dhodapkar, M Suthar, J Cohen, R Ahmed	27/09/2022
MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia	JA Zonder, J Richter, N Bumma, J Brayer, JE Hoffman, WI Bensinger, KL Wu, L Xu, D Chokshi, A Boyapati, D Cronier, Y Houvras, KR Lorenc, GS Kroog, MV Dhodapkar, S Lentzsch, D Cooper, S Jagannath	27/09/2022
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	AK Nooka, U Shanmugasundaram, N Cheedarla, H Verkerke, VV Edara, R Valanparambil, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, M Azeem, J Manalo, JM Switchenko, A Chang, SL Linderman, JD Roback, KM Dhodapkar, R Ahmed, MS Suthar, AS Neish, MV Dhodapkar	10/09/2022
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	A Chang, A Akhtar, SL Linderman, L Lai, VM Orellana-Noia, R Valanparambil, H Ahmed, VI Zarnitsyna, AA McCook-Veal, JM Switchenko, JL Koff, KA Blum, AA Ayers, CB O'Leary, MC Churnetski, S Sulaiman, M Kives, P Sheng, CW Davis, AK Nooka, R Antia, MV Dhodapkar, MS Suthar, JB Cohen, R Ahmed	10/09/2022
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). Journal for immunotherapy of cancer	MB Atkins, H Abu-Sbeih, PA Ascierto, MR Bishop, DS Chen, M Dhodapkar, LA Emens, MS Ernstoff, RL Ferris, TF Greten, JL Gulley, RS Herbst, RW Humphrey, J Larkin, KA Margolin, L Mazzarella, SS Ramalingam, MM Regan, BI Rini, M Sznol	01/09/2022
Venetoclax ex vivo functional profiling predicts improved progression-free survival. Blood cancer journal	VA Gupta, SM Matulis, BG Barwick, RD Bog, CW Shebelut, M Shanmugam, P Neri, NJ Bahlis, MV Dhodapkar, LT Heffner, CC Hofmeister, NS Joseph, S Lonial, JL Kaufman, DL Jaye, AK Nooka, LH Boise	04/08/2022
Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. Open forum infectious diseases	JC Figueiredo, FR Hirsch, LH Kushi, WN Nembhard, JM Crawford, N Mantis, L Finster, NM Merin, A Merchant, KL Reckamp, GY Melmed, J Braun, D McGovern, S Parekh, DA Corley, N Zohoori, BC Amick, R Du, PK Gregersen, B Diamond, E Taioli, C Sariol, A Espino, D Weiskopf, A Gifoni, J Brien, W Hanege, M Lipsitch, DA Zidar, A Scheck McAlearney, A Wajnberg, J LaBaer, E Yvonne Lewis, RA Binder, AM Moormann, C Forconi, S Forrester, J Batista, J Schieffelin, D Kim, G Biancon, J VanOudenhove, S Halene, R Fan, DH Barouch, G Alter, S Pinninti, SB Boppana, SK Pati, M Latting, AH Karaba, J Roback, R Sekaly, A Neish, AM Brincks, DA Granger, AB Karger, B Thyagarajan, SN Thomas, SL Klein, AL Cox, T Lucas, D Furr-Holden, K Key, N Jones, J Wrammerr, M Suthar, S Yu Wong, NM Bowman, V Simon, LD Richardson, R McBride, F Krammer, M Rana, J Kennedy, K Boehme, C Forrest, SW Granger, CD Heaney, M Knight Lapinski, S Wallet, RS Baric, L Schifanella, M Lopez, S Fernández, E Kenah, AR Panchal, WJ Britt, I Sanz, M Dhodapkar, R Ahmed, LA Bartelt, AJ Markmann, JT Lin, RS Hagan, MC Wolfgang, J Skarbinski	01/06/2022
It takes T to tango: immunotherapy in MM. Blood	VA Gupta, MV Dhodapkar	03/03/2022
Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against native-like vaccine and delta variant spike trimers. Research square	N Cheedarla, HP Verkerke, S Potlapalli, KB McLendon, A Patel, F Frank, GL Damhorst, H Wu, WH O'Sick, D Graciaa, F Hudaib, DN Alter, J Bryksin, EA Ortlund, J Guarner, S Auld, S Shah, W Lam, D Mattoon, JM Johnson, DH Wilson, MV Dhodapkar, SR Stowell, AS Neish, JD Roback	16/02/2022
Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against native-like vaccine and delta variant spike trimers. medRxiv : the preprint server for health sciences	N Cheedarla, HP Verkerke, S Potlapalli, KB McLendon, A Patel, F Frank, GL Damhorst, H Wu, WH Oâ Sick, D Graciaa, F Hudaib, DN Alter, J Bryksin, EA Ortlund, J Guarner, S Auld, S Shah, W Lam, D Mattoon, JM Johnson, DH Wilson, MV Dhodapkar, SR Stowell, AS Neish, JD Roback	02/02/2022
Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia	EM Boyle, A Rosenthal, H Ghamlouch, Y Wang, P Farmer, M Rutherford, C Ashby, M Bauer, SK Johnson, CP Wardell, Y Wang, A Hoering, C Schinke, S Thanendrarajan, M Zangari, B Barlogie, MV Dhodapkar, FE Davies, GJ Morgan, F van Rhee, BA Walker	01/02/2022
Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. Transplantation and cellular therapy	NS Joseph, VA Gupta, S Wyman, M Graiser, JL Kaufman, D Almaula, J Andrews, C Hofmeister, M Dhodapkar, LT Heffner, S Lonial, AK Nooka	01/02/2022
Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern. medRxiv : the preprint server for health sciences	R Valanparambil, J Carlisle, S Linderman, A Akthar, RL Millett, L Lai, A Chang, A McCook, J Switchenko, T Nasti, M Saini, AW Andreas Wieland, K Manning, M Ellis, K Moore, S Foster, K Floyd, M Davis-Gardner, V Viswanadh Edara, M Patel, C Steur, A Nooka, F Green, M Johns, F O Brein, U Shanmugasundaram, V Zarnitsyna, H Ahmed, L Nyhoff, G Mantus, M Garett, S Edupuganti, M Behra, R Antia, J Wrammert, M Suthar, M Dhodapkar, S Ramalingam, R Ahmed	23/01/2022
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. Blood cancer discovery	A Kaushal, AK Nooka, AR Carr, KE Pendleton, BG Barwick, J Manalo, SS McCachren, VA Gupta, NS Joseph, CC Hofmeister, JL Kaufman, LT Heffner, SM Ansell, LH Boise, S Lonial, KM Dhodapkar, MV Dhodapkar	01/11/2021
How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. Blood cancer discovery	A Ribas, MV Dhodapkar, KM Campbell, FE Davies, SD Gore, R Levy, LM Greenberger	01/11/2021
Role of MBD3-SOX2 axis in residual myeloma following pomalidomide. Leukemia	R Verma, AR Branagan, ML Xu, RA Flavell, KM Dhodapkar, MV Dhodapkar	01/11/2021
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood	VA Gupta, BG Barwick, SM Matulis, R Shirasaki, DL Jaye, JJ Keats, B Oberlton, NS Joseph, CC Hofmeister, LT Heffner, MV Dhodapkar, AK Nooka, S Lonial, CS Mitsiades, JL Kaufman, LH Boise	01/07/2021
Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias. Blood advances	AR Branagan, E Duffy, G Gan, F Li, C Foster, R Verma, L Zhang, TL Parker, S Seropian, DL Cooper, D Brandt, J Kortmansky, D Witt, TM Ferencz, KM Dhodapkar, MV Dhodapkar	09/03/2021
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. American journal of hematology	KT Maples, AK Nooka, V Gupta, NS Joseph, LT Heffner, C Hofmeister, M Dhodapkar, SM Matulis, S Lonial, LH Boise, JL Kaufman	01/03/2021
Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19. Blood cancer discovery	MV Dhodapkar, KM Dhodapkar, R Ahmed	01/01/2021
Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention. Frontiers in immunology	SS McCachren, KM Dhodapkar, MV Dhodapkar	01/01/2021
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. The Lancet. Haematology	SZ Usmani, A Hoering, S Ailawadhi, R Sexton, B Lipe, SF Hita, J Valent, M Rosenzweig, JA Zonder, M Dhodapkar, N Callander, T Zimmerman, PM Voorhees, B Durie, SV Rajkumar, PG Richardson, RZ Orlowski	01/01/2021
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. Blood cancer journal	Y Gu, BG Barwick, M Shanmugam, CC Hofmeister, J Kaufman, A Nooka, V Gupta, M Dhodapkar, LH Boise, S Lonial	14/12/2020
Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120. Clinical cancer research : an official journal of the American Association for Cancer Research	MV Dhodapkar, R Sexton, A Hoering, F Van Rhee, B Barlogie, R Orlowski	15/11/2020
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS medicine	SA Danziger, M McConnell, J Gockley, MH Young, A Rosenthal, F Schmitz, DJ Reiss, P Farmer, DV Alapat, A Singh, C Ashby, M Bauer, Y Ren, K Smith, SS Couto, F van Rhee, F Davies, M Zangari, N Petty, RZ Orlowski, MV Dhodapkar, WB Copeland, B Fox, A Hoering, A Fitch, K Newhall, B Barlogie, MWB Trotter, RM Hershberg, BA Walker, AP Dervan, AV Ratushny, GJ Morgan	01/11/2020
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	SA Holstein, A Howard, D Avigan, M Bhutani, AD Cohen, LJ Costa, MV Dhodapkar, F Gay, N Gormley, DJ Green, J Hillengass, N Korde, Z Li, S Mailankody, P Neri, S Parekh, MC Pasquini, N Puig, GD Roodman, MK Samur, N Shah, UA Shah, Q Shi, A Spencer, VJ Suman, SZ Usmani, PL McCarthy	01/10/2020
Risk-associated alterations in marrow T cells in pediatric leukemia. JCI insight	JK Bailur, SS McCachren, K Pendleton, JC Vasquez, HS Lim, A Duffy, DB Doxie, A Kaushal, C Foster, D DeRyckere, S Castellino, ML Kemp, P Qiu, MV Dhodapkar, KM Dhodapkar	20/08/2020
Smoldering Myeloma and the Art of War. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	S Lonial, MV Dhodapkar, SV Rajkumar	20/07/2020
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Journal for immunotherapy of cancer	N Shah, J Aiello, DE Avigan, JG Berdeja, IM Borrello, A Chari, AD Cohen, K Ganapathi, L Gray, D Green, A Krishnan, Y Lin, E Manasanch, NC Munshi, AK Nooka, AP Rapoport, EL Smith, R Vij, M Dhodapkar	01/07/2020
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI insight	N Bar, F Costa, R Das, A Duffy, M Samur, S McCachren, SN Gettinger, N Neparidze, TL Parker, JK Bailur, K Pendleton, R Bajpai, L Zhang, ML Xu, T Anderson, N Giuliani, A Nooka, HJ Cho, A Raval, M Shanmugam, KM Dhodapkar, MV Dhodapkar	18/06/2020
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	NS Joseph, JL Kaufman, MV Dhodapkar, CC Hofmeister, DK Almaula, LT Heffner, VA Gupta, LH Boise, S Lonial, AK Nooka	10/06/2020
Tissue-resident memory-like T cells in tumor immunity: Clinical implications. Seminars in immunology	MV Dhodapkar, KM Dhodapkar	01/06/2020
Reply to N. Biran et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	S Lonial, MV Dhodapkar, SV Rajkumar	20/04/2020
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	S Lonial, S Jacobus, R Fonseca, M Weiss, S Kumar, RZ Orlowski, JL Kaufman, AM Yacoub, FK Buadi, T O'Brien, JV Matous, DM Anderson, RV Emmons, A Mahindra, LI Wagner, MV Dhodapkar, SV Rajkumar	10/04/2020
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research	AD Cohen, N Raje, JA Fowler, K Mezzi, EC Scott, MV Dhodapkar	01/04/2020
Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. Molecular genetics and metabolism	S Nair, N Bar, ML Xu, M Dhodapkar, PK Mistry	01/04/2020
The Role of Early Intervention in High-Risk Smoldering Myeloma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	NS Joseph, MV Dhodapkar, S Lonial	01/03/2020
Game of Bones: How Myeloma Manipulates Its Microenvironment. Frontiers in oncology	T Moser-Katz, NS Joseph, MV Dhodapkar, KP Lee, LH Boise	01/01/2020
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood cancer journal	TM Schmidt, BG Barwick, N Joseph, LT Heffner, CC Hofmeister, L Bernal, MV Dhodapkar, VA Gupta, DL Jaye, J Wu, S Goyal, Z Chen, LH Boise, S Lonial, AK Nooka, JL Kaufman	25/11/2019
SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents. Clinical lymphoma, myeloma & leukemia	D Madduri, MV Dhodapkar, S Lonial, S Jagannath, HJ Cho	01/09/2019
Daratumumab in multiple myeloma. Cancer	AK Nooka, JL Kaufman, CC Hofmeister, NS Joseph, TL Heffner, VA Gupta, HC Sullivan, AS Neish, MV Dhodapkar, S Lonial	15/07/2019
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	J Mikhael, N Ismaila, MC Cheung, C Costello, MV Dhodapkar, S Kumar, M Lacy, B Lipe, RF Little, A Nikonova, J Omel, N Peswani, A Prica, N Raje, R Seth, DH Vesole, I Walker, A Whitley, TM Wildes, SW Wong, T Martin	10/05/2019
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI insight	JK Bailur, SS McCachren, DB Doxie, M Shrestha, K Pendleton, AK Nooka, N Neparidze, TL Parker, N Bar, JL Kaufman, CC Hofmeister, LH Boise, S Lonial, ML Kemp, KM Dhodapkar, MV Dhodapkar	23/04/2019
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nature communications	BG Barwick, P Neri, NJ Bahlis, AK Nooka, MV Dhodapkar, DL Jaye, CC Hofmeister, JL Kaufman, VA Gupta, D Auclair, JJ Keats, S Lonial, PM Vertino, LH Boise	23/04/2019
Navigating the Fas lane to improved cellular therapy for cancer. The Journal of clinical investigation	MV Dhodapkar	25/02/2019
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI insight	AL Garfall, EA Stadtmauer, WT Hwang, SF Lacey, JJ Melenhorst, M Krevvata, MP Carroll, WH Matsui, Q Wang, MV Dhodapkar, K Dhodapkar, R Das, DT Vogl, BM Weiss, AD Cohen, PA Mangan, EC Ayers, S Nunez-Cruz, I Kulikovskaya, MM Davis, A Lamontagne, K Dengel, ND Kerr, RM Young, DL Siegel, BL Levine, MC Milone, MV Maus, CH June	21/02/2019
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer	R Mina, NS Joseph, JL Kaufman, VA Gupta, LT Heffner, CC Hofmeister, LH Boise, MV Dhodapkar, C Gleason, AK Nooka, S Lonial	01/02/2019
Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection? Frontiers in immunology	MV Dhodapkar, KM Dhodapkar	01/01/2019
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. Journal for immunotherapy of cancer	MM Boyiadzis, MV Dhodapkar, RJ Brentjens, JN Kochenderfer, SS Neelapu, MV Maus, DL Porter, DG Maloney, SA Grupp, CL Mackall, CH June, MR Bishop	04/12/2018
The contribution of cross-talk between the cell-surface proteins CD36 and CD47-TSP-1 in osteoclast formation and function. The Journal of biological chemistry	SV Koduru, BH Sun, JM Walker, M Zhu, C Simpson, M Dhodapkar, KL Insogna	28/09/2018
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. British journal of haematology	S Jagannath, J Laubach, E Wong, K Stockerl-Goldstein, C Rosenbaum, M Dhodapkar, YM Jou, M Lynch, M Robbins, S Shelat, KC Anderson, PG Richardson	01/08/2018
MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association. Blood	NJ Weinreb, PK Mistry, BE Rosenbloom, MV Dhodapkar	31/05/2018
Checkpoint Inhibition in Myeloma: Opportunities and Challenges. Frontiers in immunology	F Costa, R Das, J Kini Bailur, K Dhodapkar, MV Dhodapkar	01/01/2018

Awards

National Institutes of Health Director's Transformative Research Award
National Cancer Institute Outstanding Investigator Award, 2016.

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
5	One star One star One star One star One star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
5	One star One star One star One star One star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One half star	24/04/2024	A malady like the one I have is mysterious and the doctor is researching ways to slow or reverse it. He is very patient and thorough in his explanations but seems to be hurried. In terms of explanations, the process needs to be refined to consider the lab process. That is, I have blood drawn on a given visit and the results are reported on my portal but there is no physician follow-up to explain and interpret the results. Therefore, I don't know if my lab results are expected, not expected, positive, or disappointing to the doctor.
One star One star One star One star One star	21/03/2024	When I could not get answers that made sense to me regarding my medical need I called Emory and it was the best decision I could have made. I was receiving a different diagnosis with each Dr prior to Emory and none of them made sense to me. The Physicians at Emory seemed to know the correct answers immediately, and performed tests that proved their diagnosis. It may have saved my life.
One star One star One star One star One star	31/01/2024	Everything is fine
One star One star One star One star One star	12/01/2024	He is ver good at treating me like an adult, like a partner in my care. I really appreciate that. He takes the care to communicate with me.
One star One star One star One star One star	04/10/2023	He did try to see things from the patients perspective and that was appreciated. It is a very confusing disorder.
One star One star One star One star One star	23/06/2023	A very caring and pleasant doctor
One star One star One star One star One star	03/05/2023	Dr. Dhodapkar always ready to listen and have answers. He encourages me. Not too quick to give me medications until he finds out the source of the problem.
One star One star One star One star One star	13/01/2023	Dr. D is a very no nonsense to the point Dr. Which I appreciate! You can tell he is a kind man as well. He has his patient's health as his priority. He works very well with my Oncologist too.
One star One star One star One star One star	10/01/2023	Dr Dhodapkar always shows great concern for my wellbeing. He listens to my questions and concerns. He always encourages me in my walk with this horrible disease.
One star One star One star One star One star	07/12/2022	I feel very comfortable that Dr Dhodapcar is on top of my healthcare issues. He gives me confidence in the treatment.
One star One star One star One star One star	12/07/2022	Top notch care.